Status:
COMPLETED
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
Lead Sponsor:
Celgene
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
60+ years
Brief Summary
Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival ...
Detailed Description
Following the baseline enrolment visit, the following data corresponding to the patient's visits scheduled according to routine clinical practice will be collected in accordance with the following mod...
Eligibility Criteria
Inclusion
- Patient of both sexes, aged 65 years and older.
- Any race, nationality or socioeconomic status.
- AML (defined according to WHO 2016 criteria de novo, with previous hematological history or secondary.
- Diagnosis date later than 1st November 2017 and later than each center activation date.
- Patients on first line treatment with any therapeutic strategy (intensive, attenuated or palliative).
- Having given informed consent prior to start the data collection.
Exclusion
- Inability to understand the informed consent form.
- AML previously treated (with or without HSCT).
- Acute promyelocytic leukemia.
- Participation in a clinical trial that includes first-line treatment for AML.
- Do not grant consent.
Key Trial Info
Start Date :
February 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT03435341
Start Date
February 28 2018
End Date
April 30 2020
Last Update
May 21 2021
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Jerez
Jerez de la Frontera, Andalucía/Cádiz, Spain, 11404
2
Hospital Virgen de las Nieves
Granada, Andalucía/Granada, Spain, 18014
3
Hospital Carlos Haya
Málaga, Andalucía/Málaga, Spain, 29010
4
Hospital Virgen del Rocio
Seville, Andalucía/Sevilla, Spain, 41013